The operational increase was driven by an increase in revenues for Eliquis, Padcev, the Vyndaqel family, Lorbrena, Nurtec ODT/Vydura, Oncology biosimilars and several other products across categories
Padcev is being jointly developed and commercialized with Astellas in the U.S., with Pfizer having commercialization rights in all countries in North and South America
no findingread · nothing bore on it
It held on this filing. No finding was written because nothing in it bore on the reason — the sentences it was read against are below.
the evidence · every sentence checkedtwo sentences · whole, uncut
the claims it rests on
“The operational increase was driven by an increase in revenues for Eliquis, Padcev, the Vyndaqel family, Lorbrena, Nurtec ODT/Vydura, Oncology biosimilars and several other products across categories”
“Padcev is being jointly developed and commercialized with Astellas in the U.S., with Pfizer having commercialization rights in all countries in North and South America”